Insulin detemir. Novo Nordisk

Barlocco, D.

Current Opinion in Investigational Drugs 4(4): 449-454

2003


ISSN/ISBN: 1472-4472
PMID: 12808886
Document Number: 561362
Insulin detemir (NN-304) is a soluble, long-acting insulin analog being developed by Novo Nordisk for the potential treatment of type 1 and 2 diabetes. As of February 2003, Novo Nordisk was expecting both US and EU approval in the first half of 2004. In December 2002, Novo Nordisk submitted an NDA to the FDA and an NDS to the Canadian Biologics & Genetics Therapeutic Directorate for the approval of insulin detemir for the treatment of diabetes mellitus.

Document emailed within 1 workday
Secure & encrypted payments